Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Amgen has licensed the exclusive right to use the Company's
View HTML
Toggle Summary CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
— Collaboration enables creation of PDCs using CytomX's Probody Platform and ImmunoGen's ADC technology — SOUTH SAN FRANCISCO & WALTHAM, Mass. --(BUSINESS WIRE)-- CytomX Therapeutics , the Probody™ therapeutics company, and ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops
View HTML
Toggle Summary Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to
View HTML
Toggle Summary Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
View HTML
Toggle Summary First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers
First clinical findings presented with ImmunoGen's folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853. Preliminary evidence of activity seen in dose-finding portion of trial. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
View HTML
Toggle Summary ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® (pembrolizumab) for the Treatment of Ovarian Cancer
− ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer
View HTML
Toggle Summary ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
View HTML
Toggle Summary ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters' full exercise of their option to purchase
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 5, 2017 to discuss its first quarter 2017
View HTML